|
|
Suppliers for
LY2562175
|
Properties | CAS |
1103500-20-4 |
|
4 Registered suppliers
Description : LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. It was developed by Eli Lilly and Company and in clinic phase 1 trials with no progress. - Molecular Weight :540.44
- Boiling Point :740.1±60.0 °C | Condition: Press: 760 Torr
- Purity :> 98%
Molecular Formula : C28H27Cl2N3O4 Canonical SMILES : CN1C=C(C2=C1C=C(C=C2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C(=O)O InChI : InChI=1S/C28H27Cl2N3O4/c1-32-14-20(28(34)35)19-8-7-17(13-24(19)32)33-11-9-18(10-12-33)36-15-21-26(31-37-27(21)16-5-6-16)25-22(29)3-2-4-23(25)30/h2-4,7-8,13-14,16,18H,5-6,9-12,15H2,1H3,(H,34,35) InChIKey : RPVDFHPBGBMWID-UHFFFAOYSA-N Solubility : 10 mM in DMSO Appearance : Solid powder Application : LY2562175 has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. Storage : -20°C Freezer Synonyms : LY2562175; LY 2562175; LY-2562175;6-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid
More details are to be found here
Detailed information on the suppliers of
LY2562175
|
Properties:
... more properties and specification on LY2562175
|
|
Privileged suppliers
Last update 2024-06-12
|